Indicated for: hematopoietic stem cell mobilization
Route of administration: injectable
Substance: plerixafor (CXCR4 antagonist)
ATC: L03AX16 (Antineoplastic and immunomodulating agents | Immunostimulants | Other immunostimulants)
Plerixafor is a medication used to mobilize hematopoietic stem cells from the bone marrow into the bloodstream for collection and transplantation.
It is used in combination with granulocyte colony-stimulating factors (G-CSF) in patients with lymphoma or multiple myeloma who require autologous stem cell transplantation.
Plerixafor works by blocking the CXCR4 receptor, which causes the release of stem cells from the bone marrow into the bloodstream.
This mobilization is essential for collecting a sufficient number of stem cells needed for transplantation.
Common side effects include nausea, diarrhea, fatigue, headaches, and injection site reactions.
In rare cases, severe allergic reactions may occur, such as difficulty breathing, skin rashes, or facial swelling.
It is important for patients to be closely monitored during treatment with plerixafor, and the medication should be administered under the supervision of a specialist.
Patients should inform their doctor about any other medications they are taking or pre-existing conditions to avoid potential interactions or complications.